Via The Wellness Company
What if two decades-old medications could help open new doors in cancer research?
A comprehensive review from researchers affiliated with The Wellness Company and the McCullough Foundation examines the potential anticancer activity of ivermectin and mebendazole.
The most intriguing finding? These medications appear to affect cancer cells in different, potentially complementary ways.
And researchers believe those differences deserve a closer look.
Ivermectin has demonstrated effects on cancer-cell growth signals, metabolism, and immune-related pathways in laboratory studies.
Mebendazole has shown the ability to disrupt microtubules—the internal structures cancer cells need to divide.
Different mechanisms. A shared area of scientific interest.
The possibility of complementary effects is one reason researchers are interested in investigating these medications further.
EXPLORE THE RESEARCH
Preclinical research has documented potential effects on several processes involved in cancer growth and survival:
The breadth of these findings gives researchers multiple avenues to investigate.
The review brings together preclinical findings involving 25 cancer types, highlighting the range of research already underway.
Now comes the important next step: rigorous clinical trials.
Researchers need to determine whether these laboratory findings can translate into safe, meaningful benefits for patients.
The potential deserves investigation. The answers will come from stronger clinical evidence.
READ THE FULL RESEARCH
Explore the science behind cancer, the role of the immune system, and prevention strategies to better understand today’s research and evolving treatment landscape.
Download your free Understanding Cancer Guide now
Tweet
Continue reading...
[ H/T The Burning Platform ]
Cancer Research: Two Drugs, Multiple Targets, Emerging Evidence
What if two decades-old medications could help open new doors in cancer research?
A comprehensive review from researchers affiliated with The Wellness Company and the McCullough Foundation examines the potential anticancer activity of ivermectin and mebendazole.
The most intriguing finding? These medications appear to affect cancer cells in different, potentially complementary ways.
And researchers believe those differences deserve a closer look.
Two Drugs. Different Targets.
Ivermectin has demonstrated effects on cancer-cell growth signals, metabolism, and immune-related pathways in laboratory studies.
Mebendazole has shown the ability to disrupt microtubules—the internal structures cancer cells need to divide.
Different mechanisms. A shared area of scientific interest.
The possibility of complementary effects is one reason researchers are interested in investigating these medications further.
EXPLORE THE RESEARCH
Five Areas Worth Watching
Preclinical research has documented potential effects on several processes involved in cancer growth and survival:
- Cell growth: Interfering with signals that drive cancer-cell division.
- DNA repair: Affecting how cells respond to genetic damage.
- Blood-vessel formation: Investigating pathways that help supply tumors.
- Drug resistance: Exploring mechanisms that may allow cancer cells to resist treatment.
- Immune activity: Studying interactions between cancer cells and immune defenses.
The breadth of these findings gives researchers multiple avenues to investigate.
The Next Chapter of Cancer Research
The review brings together preclinical findings involving 25 cancer types, highlighting the range of research already underway.
Now comes the important next step: rigorous clinical trials.
Researchers need to determine whether these laboratory findings can translate into safe, meaningful benefits for patients.
The potential deserves investigation. The answers will come from stronger clinical evidence.
READ THE FULL RESEARCH
Explore the science behind cancer, the role of the immune system, and prevention strategies to better understand today’s research and evolving treatment landscape.
Download your free Understanding Cancer Guide now
ORDER NOW
Tweet
Continue reading...
[ H/T The Burning Platform ]
